Hepatocellular carcinoma (HCC) remains a highly prevalent and lethal malignancy. The previously poor prognosis associated with HCC is undergoing a dramatic transformation due to the advent of effective systemic therapies. Despite significant progress, the molecular mechanisms underlying immune response and evasion in HCC remain elusive. While the metabolic hallmarks of cancer have been extensively studied, the metabolic state of immune cells is less well elucidated. Immunometabolism is an emerging field that focuses on the metabolic modulation of immune cells as a crucial determinant of their phenotype and function in tumor microenvironment (TME). Despite the remarkable advances in cancer immunotherapy, our understanding of the metabolic interactions between tumor and immune cells within the TME and during immunotherapy remains limited. Therefore, an in-depth understanding of immunometabolism in TME may provide an innovative therapeutic perspective for HCC treatment.
In this Research Topic, we provide an integrated description to unravel the intricate interplay between metabolic regulation and the immune response in HCC, along with their implications on therapeutic targeting and overcoming therapy resistance. We welcome submissions in the relevant fields, with a particular focus on, but not limited to:
1) Immune subtype of HCC
2) Novel roles of immunometabolism in HCC progression and drug resistance
3) Predictive or therapeutic targets of immunometabolism in HCC
4) Implications of cancer and immune cell metabolism on immunotherapy for HCC
5) Emerging approaches for testing and modeling tumor immunometabolism interactions
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Hepatocellular carcinoma (HCC) remains a highly prevalent and lethal malignancy. The previously poor prognosis associated with HCC is undergoing a dramatic transformation due to the advent of effective systemic therapies. Despite significant progress, the molecular mechanisms underlying immune response and evasion in HCC remain elusive. While the metabolic hallmarks of cancer have been extensively studied, the metabolic state of immune cells is less well elucidated. Immunometabolism is an emerging field that focuses on the metabolic modulation of immune cells as a crucial determinant of their phenotype and function in tumor microenvironment (TME). Despite the remarkable advances in cancer immunotherapy, our understanding of the metabolic interactions between tumor and immune cells within the TME and during immunotherapy remains limited. Therefore, an in-depth understanding of immunometabolism in TME may provide an innovative therapeutic perspective for HCC treatment.
In this Research Topic, we provide an integrated description to unravel the intricate interplay between metabolic regulation and the immune response in HCC, along with their implications on therapeutic targeting and overcoming therapy resistance. We welcome submissions in the relevant fields, with a particular focus on, but not limited to:
1) Immune subtype of HCC
2) Novel roles of immunometabolism in HCC progression and drug resistance
3) Predictive or therapeutic targets of immunometabolism in HCC
4) Implications of cancer and immune cell metabolism on immunotherapy for HCC
5) Emerging approaches for testing and modeling tumor immunometabolism interactions
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.